Most recently, the results from clinical trials of the new HER2-targeting agents pertuzumab and trastuzumab emtansine have been reported, and these agents can be considered as options in the HER2-positive breast cancer treatment algorithm [19, 20]. Here, ERBB2 is linked to breast carcinoma.